- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
"Value" Decision by NICE Met With Disapproval
Both, the scientific community and a charitable organization, Prostate Cancer UK, have criticized the drug approval body for not offering abiraterone to sufferers until after chemotherapy.
The decision not to offer a life-extending drug to prostate cancer sufferers until after they have received chemotherapy is a "kick in the teeth" for patients, a charity has said.
Prostate Cancer UK said the drug could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects.
The charity said the National Institute for Health and Care Excellence's (Nice) decision was unjust.
Scientists have also expressed their disappointment over the health watchdog's guidance not to recommend the drug in this circumstance. Experts from the Institute of Cancer Research (ICR) said there was clear evidence abiraterone was beneficial for patients before they underwent chemotherapy.
In final draft guidance, Nice said that the drug should not be widely used in the NHS in England to treat prostate cancer patients whose cancer has spread and who have previously received another type of hormone therapy before they are given chemotherapy.
Read the report here: http://bit.ly/1t5K7Gc
Source: The Guardian
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
